Menu
Search
|

Menu

Close
X

Immune Pharmaceuticals Inc IMNP.OQ (NASDAQ Stock Exchange Capital Market)

0.19 USD
-0.00 (-1.81%)
As of Jun 22
chart
Previous Close 0.19
Open 0.20
Volume 164,973
3m Avg Volume 110,842
Today’s High 0.20
Today’s Low 0.18
52 Week High 3.43
52 Week Low 0.18
Shares Outstanding (mil) 10.58
Market Capitalization (mil) 15.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.146
FY17
-2.156
FY16
-10.822
FY15
-18.914
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
--
5.71
Price to Book (MRQ)
vs sector
--
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
--
16.46
LT Debt to Equity (MRQ)
vs sector
--
12.19
Return on Investment (TTM)
vs sector
-201.88
14.38
Return on Equity (TTM)
vs sector
-1,487.29
16.08

EXECUTIVE LEADERSHIP

Elliot Maza
President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary, Director, Since 2017
Salary: --
Bonus: --
Anthony Fiorino
Chief Operating Officer, Chief Medical Officer, Since 2017
Salary: --
Bonus: --
John Clark
Controller, Since 2017
Salary: --
Bonus: --
Cameron Durrant
Lead Independent Director, Since 2015
Salary: --
Bonus: --
Daniel Teper
Director, Since 2017
Salary: $342,456.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

550 Sylvan Ave Ste 101
ENGLEWOOD CLIFFS   NJ   07632-3115

Phone: +1201.4642677

Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The Company is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The Company’s oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

SPONSORED STORIES